Strategic IP License Highlight that Forward Pharma entered into a major IP license with Biogen in 2017, indicating a potential pivot point and a refreshed licensing strategy for durable DMF-based opportunities or spin-offs in related inflammatory and neurological indications.

Phase III History Leverage the historical phase III efforts on FP187 for psoriasis to identify legacy trial data, potential repurposing angles, or partnership opportunities with firms focusing on dermatology, autoimmune diseases, or repurposing strategies for DMF derivatives.

Liquidation Outcome Note that the company completed voluntary solvent liquidation in 2025, which may imply available IP assets, licenses, or residual programs that could be acquired or licensed via sale or collaboration with acquirers seeking DMF-related technology or neuroscience assets.

Strategic Partnerships Recognize past collaborations such as with Ixchel Pharma and the broader network around Friedreich's ataxia, suggesting a path to re-engage related biotech partners for co-development or technology transfer opportunities in rare neurological indications.

Financial Signals Revenue remains low (<$1M) but a $1.25B upfront Biogen license indicates significant value recognition in DMF-based platforms; approach in BD should target licensing, asset acquisition, or collaboration with financial and pharmaceutical players seeking DMF-derived assets or IP consolidation.